Cieślikowski, W.A.; Milecki, P.; Świerczewska, M.; Ida, A.; Kasperczak, M.; Jankowiak, A.; Nowicki, M.; Pantel, K.; Alix-Panabières, C.; Zabel, M.;
et al. Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. J. Pers. Med. 2023, 13, 608.
https://doi.org/10.3390/jpm13040608
AMA Style
Cieślikowski WA, Milecki P, Świerczewska M, Ida A, Kasperczak M, Jankowiak A, Nowicki M, Pantel K, Alix-Panabières C, Zabel M,
et al. Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. Journal of Personalized Medicine. 2023; 13(4):608.
https://doi.org/10.3390/jpm13040608
Chicago/Turabian Style
Cieślikowski, Wojciech A., Piotr Milecki, Monika Świerczewska, Agnieszka Ida, Michał Kasperczak, Agnieszka Jankowiak, Michał Nowicki, Klaus Pantel, Catherine Alix-Panabières, Maciej Zabel,
and et al. 2023. "Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer" Journal of Personalized Medicine 13, no. 4: 608.
https://doi.org/10.3390/jpm13040608
APA Style
Cieślikowski, W. A., Milecki, P., Świerczewska, M., Ida, A., Kasperczak, M., Jankowiak, A., Nowicki, M., Pantel, K., Alix-Panabières, C., Zabel, M., Antczak, A., & Budna-Tukan, J.
(2023). Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. Journal of Personalized Medicine, 13(4), 608.
https://doi.org/10.3390/jpm13040608
